500
0
0
Skip to Content
Lung Cancer Europe | Advocacy and Access for Lung Cancer in Europe
Overview
Our Board
Brand hub
Contact
News
Policy
Organisation news
Events
Access
Prevention & risk
11th Report
11th Report Press Release
10th Report
English
Lung Cancer Europe | Advocacy and Access for Lung Cancer in Europe
Overview
Our Board
Brand hub
Contact
News
Policy
Organisation news
Events
Access
Prevention & risk
11th Report
11th Report Press Release
10th Report
English
Folder: Who We Are
Back
Overview
Our Board
Brand hub
Contact
Folder: News
Back
News
Policy
Organisation news
Events
Access
Prevention & risk
Folder: Annual Reports
Back
11th Report
11th Report Press Release
10th Report
English
Back
The Microbiome and Lung Cancer: How Gut Bacteria Could Change Treatment
News, Treatment, Research Web Team 04/07/2026 News, Treatment, Research Web Team 04/07/2026

The Microbiome and Lung Cancer: How Gut Bacteria Could Change Treatment

Read More
President’s Mid Year Report: January to June 2026
News, Advocacy Web Team 01/07/2026 News, Advocacy Web Team 01/07/2026

President’s Mid Year Report: January to June 2026

Read More
Access to Treatment Atlas: compare lung cancer treatment access across Europe
News, Advocacy, Treatment Web Team 01/07/2026 News, Advocacy, Treatment Web Team 01/07/2026

Access to Treatment Atlas: compare lung cancer treatment access across Europe

Read More
Lung Cancer Europe updates its identity
News, Advocacy Web Team 01/07/2026 News, Advocacy Web Team 01/07/2026

Lung Cancer Europe updates its identity

Read More
What the EU Critical Medicines Act means for lung cancer
News, Treatment, Advocacy Web Team 01/07/2026 News, Treatment, Advocacy Web Team 01/07/2026

What the EU Critical Medicines Act means for lung cancer

Read More
England catches up on cemiplimab for advanced lung cancer
News, Access, Treatment Web Team 01/07/2026 News, Access, Treatment Web Team 01/07/2026

England catches up on cemiplimab for advanced lung cancer

Read More
HARMONi-7: European sites now open for Phase 3 ivonescimab trial in high PD-L1 NSCLC
Treatment, News, Advocacy Web Team 01/07/2026 Treatment, News, Advocacy Web Team 01/07/2026

HARMONi-7: European sites now open for Phase 3 ivonescimab trial in high PD-L1 NSCLC

Read More
EU Progress on 2030 Clinical Trial Targets: What It Means for Lung Cancer
News, Advocacy, Treatment, Access Web Team 30/06/2026 News, Advocacy, Treatment, Access Web Team 30/06/2026

EU Progress on 2030 Clinical Trial Targets: What It Means for Lung Cancer

Read More
Could innovative medicines save more than they cost? What this new report means for lung cancer
Advocacy, Treatment, News, Innovation Web Team 25/06/2026 Advocacy, Treatment, News, Innovation Web Team 25/06/2026

Could innovative medicines save more than they cost? What this new report means for lung cancer

Read More
Lung cancer in women: what a new study shows about treatment side effects
Treatment, Research, News Web Team 24/06/2026 Treatment, Research, News Web Team 24/06/2026

Lung cancer in women: what a new study shows about treatment side effects

Read More
Early-onset lung cancer: why are more younger adults being diagnosed?
Prevention & risk, Research, News Web Team 22/06/2026 Prevention & risk, Research, News Web Team 22/06/2026

Early-onset lung cancer: why are more younger adults being diagnosed?

Read More
Biomarker testing is moving faster than ever. Is Europe keeping up?
Research, Treatment, Advocacy, News Web Team 20/06/2026 Research, Treatment, Advocacy, News Web Team 20/06/2026

Biomarker testing is moving faster than ever. Is Europe keeping up?

Read More
Lung cancer and heart health: understanding the two-way connection
Prevention & risk, Advocacy, News, Treatment Web Team 20/06/2026 Prevention & risk, Advocacy, News, Treatment Web Team 20/06/2026

Lung cancer and heart health: understanding the two-way connection

Read More
Hotter Summers, Dirtier Air: Heatwaves and Lung Cancer in Europe
Prevention & risk, Advocacy, News Web Team 19/06/2026 Prevention & risk, Advocacy, News Web Team 19/06/2026

Hotter Summers, Dirtier Air: Heatwaves and Lung Cancer in Europe

Read More
Could ageing lung cells increase lung cancer risk?
Prevention & risk, News, Research Web Team 16/06/2026 Prevention & risk, News, Research Web Team 16/06/2026

Could ageing lung cells increase lung cancer risk?

Read More
Small cell lung cancer and mental health: experiences reported by Europeans impacted by the disease
Advocacy, LuCE News, News Web Team 14/06/2026 Advocacy, LuCE News, News Web Team 14/06/2026

Small cell lung cancer and mental health: experiences reported by Europeans impacted by the disease

Read More
Lung cancer in people who have never smoked: what the evidence now shows
Prevention & risk, Advocacy, Research, LuCE News, News Web Team 13/06/2026 Prevention & risk, Advocacy, Research, LuCE News, News Web Team 13/06/2026

Lung cancer in people who have never smoked: what the evidence now shows

Read More
GLP-1 drugs and lung cancer: what the ASCO 2026 evidence shows, and what it does not
LuCE News, News, Treatment, Research Web Team 12/06/2026 LuCE News, News, Treatment, Research Web Team 12/06/2026

GLP-1 drugs and lung cancer: what the ASCO 2026 evidence shows, and what it does not

Read More
What Could a New Iron Discovery Mean for Lung Cancer Immunotherapy?
LuCE News, News, Treatment, Advocacy Web Team 11/06/2026 LuCE News, News, Treatment, Advocacy Web Team 11/06/2026

What Could a New Iron Discovery Mean for Lung Cancer Immunotherapy?

New research published in Nature Cancer has identified iron accumulation as a trigger for the destruction of CAR-T immune cells. We explore what this unexpected finding could mean for the future of lung cancer treatment.

Read More
PFAS restrictions and medicines: what is the EU proposing, and how it might affect lung cancer treatment
LuCE News, News, Advocacy, Research Web Team 10/06/2026 LuCE News, News, Advocacy, Research Web Team 10/06/2026

PFAS restrictions and medicines: what is the EU proposing, and how it might affect lung cancer treatment

The EU is consulting on new restrictions on PFAS chemicals, also known as “forever chemicals.” Lung Cancer Europe explains what the proposed regulation involves, why it matters for medicine supply, and how we are engaging with the process.

Read More
Older Posts

With Thanks to Our Supporters

Lung Cancer Europe is grateful to the partners who share our commitment to people affected by lung cancer. Their support helps us turn our mission into action across research, education and advocacy.

Accord Healthcare Amgen Bayer AstraZeneca BeOne Medicines BioNTech Blueprint Medicines Bristol Myers Squibb Boehringer Ingelheim Daiichi Sankyo Genmab Gilead Johnson & Johnson Lilly Merck Group MSD Novartis Novocure Pfizer PharmaCosmos PharmaMar Pierre Fabre Regeneron Roche Takeda Thermo Fisher

Connect with us on LinkedIn

Stay in the loop

You can subscribe to updates from Lung Cancer Europe by signing up to our monthly newsletter below. Our newsletter goes out on 1st of every month and we also send out news bulletins and updates.

By signing up, you agree to receive emails from Lung Cancer Europe. You can unsubscribe at any time. Read our Privacy Policy to learn how we handle your data.

PRIVACY POLICY

© Lung Cancer Europe 2026 | Designed by Laura Jones